Contrasting Acumen Pharmaceuticals (NASDAQ:ABOS) and Genetic Technologies (NASDAQ:GENE)

Genetic Technologies (NASDAQ:GENE) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Analyst Recommendations

This is a summary of recent ratings for Genetic Technologies and Acumen Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genetic Technologies	0	0	0	0	0.00
Acumen Pharmaceuticals	0	0	3	1	3.25

Acumen Pharmaceuticals has a consensus price target of $9.00, indicating a potential upside of 324.53%. Given Acumen Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Genetic Technologies.

Risk and Volatility

Genetic Technologies has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of -0.07, meaning that its stock price is 107% less volatile than the S&P 500.

Valuation & Earnings

This table compares Genetic Technologies and Acumen Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genetic Technologies	$5.03 million	0.74	-$7.88 million	N/A	N/A
Acumen Pharmaceuticals	N/A	N/A	-$52.37 million	($1.38)	-1.54

Genetic Technologies has higher revenue and earnings than Acumen Pharmaceuticals.

Insider & Institutional Ownership

0.6% of Genetic Technologies shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 6.5% of Genetic Technologies shares are owned by company insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Genetic Technologies and Acumen Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genetic Technologies	N/A	N/A	N/A
Acumen Pharmaceuticals	N/A	-32.99%	-27.99%

Summary

Acumen Pharmaceuticals beats Genetic Technologies on 6 of the 11 factors compared between the two stocks.

About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.